PARP1 Inhibitor and Trabectedin Combination Does Not Increase Tumor Mutational Burden in Advanced Sarcomas—A Preclinical and Translational Study

SIMPLE SUMMARY: Immunotherapy has revolutionized cancer treatment, but not for all tumor types. Indeed, sarcomas are considered “immune-cold” tumors, which are relatively unresponsive to immunotherapy. One strategy to potentiate immunotherapy efficacy is to increase tumor immunogenicity, for instanc...

Descripción completa

Detalles Bibliográficos
Autores principales: Pignochino, Ymera, Crisafulli, Giovanni, Giordano, Giorgia, Merlini, Alessandra, Berrino, Enrico, Centomo, Maria Laura, Chiabotto, Giulia, Brusco, Silvia, Basiricò, Marco, Maldi, Elena, Pisacane, Alberto, Leuci, Valeria, Sangiolo, Dario, D’Ambrosio, Lorenzo, Aglietta, Massimo, Kasper, Bernd, Bardelli, Alberto, Grignani, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699802/
https://www.ncbi.nlm.nih.gov/pubmed/34944915
http://dx.doi.org/10.3390/cancers13246295

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699802/
https://www.ncbi.nlm.nih.gov/pubmed/34944915
http://dx.doi.org/10.3390/cancers13246295

Ejemplares similares